A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

Status unconfirmed · Phase 1/Phase 2

Conditions studied: HIV Infections

In brief

Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.

Key facts

Study ID

NCT00048217

Run by

Trimeris

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completion T1249-102;
• Currently failing a T-20 containing regimen

You may not qualify if…

• Non-completion of T1249-102.

Where it is running

• Trimeris — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.